Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

NERVGEN PHARMA CORP.

CIK 1751912Updated Nov 19, 2026

NGEN price & chart

Provider market data

Loading TradingView…

NASDAQ:NGEN on TradingView ↗

TradingView · Data may be delayed

About the company

NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to counteract the inhibitory effects of chondroitin sulfate proteoglycans. NVG-291 has received Breakthrough Therapy designation from the FDA for the treatment of chronic traumatic cervical motor-incomplete SCI, based on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating the potential for substantial improvement over available therapy on one or more clinically significant endpoints. NVG-291 has also received FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

6-K · 2026-11-18 · 0001104659-26-129692

Company description from the cited filing.

Financials

FY 2025 · CAD
Revenue— · FY 2025
Net income— · FY 2025
Assets—CAD · FY 2025
Cash— · FY 2025
Operating income— · FY 2025
Diluted EPS-0.61CAD/shares · FY 2025
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2025FY 2024
Cash flows from operating activities:
Profit or LossCAD-44,117,305
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

-24,250,049
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

Additional Financial Items
AdjustmentsForSharebasedPaymentsCAD5,394,914
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

6,039,724
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD-452,134
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

294,337
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

GeneralAndAdministrativeExpenseCAD11,172,046
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

9,365,129
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD100,926
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

100,926
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

ProceedsFromIssuingSharesCAD16,884,659
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

23,011,788
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024
Additional Financial Items
BasicEarningsLossPerShareCAD/shares-0.61
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

-0.36
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

DepreciationRightofuseAssetsCAD—22,490
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

DilutedEarningsLossPerShareCAD/shares-0.61
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

-0.36
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

FinanceIncomeCAD333,415
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

812,617
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

GeneralAndAdministrativeExpenseCAD11,172,046
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

9,365,129
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

InterestExpenseOnLeaseLiabilitiesCAD3,691
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

9,340
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

ResearchAndDevelopmentExpenseCAD13,907,206
Source

40-F · 2026-03-31 · 0001104659-26-037357

2025-01-01 to 2025-12-31

15,811,020
Source

40-F · 2026-03-31 · 0001104659-26-037357

2024-01-01 to 2024-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

tm2630103d1_ex99-1.htm · 6-K · 2026-11-18

Exhibit 99.1 NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer Dr. Jackson brings expertise in innovative neuroscience trial design, leading pivotal Phase 3 studies and supporting FDA approval He will lead execution of the ongoing Phase 3 RESTORE study and support clinical expansion of NVG-291 as a potential pipeline-in-a-product MIAMI - November 18, 2026 - NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company devel…

6-K · 2026-11-18 · 0001104659-26-129692

Read attachment ↗
tm2629739d1_ex99-1.htm · 6-K · 2026-11-16

Exhibit 99.1 Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and nine months ended September 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at September 30, 2026 December 31, 2025 Assets Current ass…

6-K · 2026-11-16 · 0001104659-26-128401

Read attachment ↗
tm2629739d1_ex99-2.htm · 6-K · 2026-11-16

Exhibit 99.2 Management’s Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the three and nine months ended September 30, 2026 and 2025 Effective Date: November 16, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS The following discussion is management’s assessment and analysis of the results of operations and financial condition of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed consolidated in…

6-K · 2026-11-16 · 0001104659-26-128401

Read attachment ↗
tm2627645d1_ex99-1.htm · 6-K/A · 2026-10-16

Exhibit 99.1 Amended and Restated Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and six months ended June 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at June 30, December 31, …

6-K/A · 2026-10-16 · 0001104659-26-116634

Read attachment ↗
tm2627645d1_ex99-2.htm · 6-K/A · 2026-10-16

Exhibit 99.2 Amended and Restated Management’s Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the three and six months ended June 30, 2026 and 2025 Effective Date: October 16, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS The following discussion is management’s assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed …

6-K/A · 2026-10-16 · 0001104659-26-116634

Read attachment ↗
ngen-20251231xex99d2.htm · 40-F/A · 2026-10-16

Exhibit 99.2 Amended and Restated Consolidated financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the years ended December 31, 2025 and 2024 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors NervGen Pharma Corp.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statements of financial position of NervGen Pharma Corp. (the Company) as of December 31, 2025 and 2024,…

40-F/A · 2026-10-16 · 0001104659-26-116627

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.